GSDMD ligand-1
GSDMD ligand-1 (compound A5) is a synthetic intermediate. GSDMD ligand-1 is used for conjugation with Thalidomide (HY-14658)/CRBN linker fragments to construct PROTACs targeting GSDMD. GSDMD ligand-1 can be used in cancer-related research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Formel: C26H23F2N3O4
- Molecular Weight:479.48
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
GSDMD |
Chemical Information
-
Molecular Weight 479.48
-
Formel C26H23F2N3O4
-
SMILES
OC(C1=CC=C(C=C1)C(NC2=CC=C(C=C2)N3CCN(CC3)C(CC4=C(C=C(C=C4)F)F)=O)=O)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Keywords
- GSDMD ligand-1
- GSDMD ligand1
- GSDMD ligand 1
- Drug Intermediate
- Synthetic Intermediate
- GSDMD ligand
- GSDMD binder
- GSDMD warhead
- 4-((4-(4-(2-(2
- 4-difluorophenyl)acetyl)piperazin-1-yl)phenyl)carbamoyl)benzoic acid
- PGC analog
- PROTAC building block
- CRBN-recruiting GSDMD PROTAC precursor
- pyroptosis research intermediate
- inflammasome research intermediate
- full-length GSDMD targeting scaffold
- PGC-01 precursor intermediate
- Inhibitor
- inhibitor
- inhibit